Putting participants and study partners FIRST when clinical trials end early-Reference-Cited by-同舟云学术

Putting participants and study partners FIRST when clinical trials end early

Published:2022-08-02 Issue:12 Volume:18 Page:2736-2746
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Largent Emily A.¹,Walter Sarah²,Childs Nancy³,Dacks Penny A.⁴,Dodge Shana⁴,Florian Hana⁵,Jackson Jonathan⁶,Llibre Guerra Jorge J.⁷,Iturriaga Erin⁸,Miller David S.⁹,Moreno Monica¹⁰,Nosheny Rachel L.¹¹,Obisesan Thomas O.¹²,Portacolone Elena¹³,Siddiqi Bernadette¹⁴,Silverberg Nina¹⁵,Warren Rueben C.¹⁶,Welsh‐Bohmer Kathleen A.¹⁷,Edelmayer Rebecca M.¹⁰,

Affiliation:

1. Department of Medical Ethics and Health Policy University of Pennsylvania Perelman School of Medicine Philadelphia PA USA

2. Alzheimer's Therapeutic Research Institute University of Southern California San Diego CA USA

3. Care Partner Philadelphia PA USA

4. The Association for Frontotemporal Degeneration King of Prussia PA USA

5. AbbVie Neuroscience Clinical Development North Chicago IL USA

6. Department of Neurology Harvard Medical School Massachusetts General Hospital Boston MA USA

7. Department of Neurology Washington University School of Medicine in St. Louis St. Louis MO USA

8. National Institutes of Health National Heart, Lung, and Blood Institute Bethesda MD USA

9. Signant Health Blue Bell PA USA

10. Alzheimer's Association Chicago IL USA

11. Department of Psychiatry and Behavioral Sciences VA Advanced Imaging Research Center San Francisco Veterans Administration Medical Center University of California San Francisco San Fancisco CA USA

12. Division of Geriatrics Department of Medicine Howard University and Hospital Washington DC USA

13. Institute for Health & Aging Philip Lee Institute for Health Policy Studies University of California San Francisco San Francisco CA USA

14. The Michael J. Fox Foundation for Parkinson's Research New York NY USA

15. National Institutes of Health National Institute on Aging Bethesda MD USA

16. National Center for Bioethics in Research and Health Care Tuskegee University Tuskegee AL USA

17. Department of Psychiatry Duke University School of Medicine Durham NC USA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12732

Reference34 articles.

1. Merck.Merck Announces Discontinuation of APECS Study Evaluating Verubecestat (MK‐8931) for the Treatment of People with Prodromal Alzheimer's Disease 2018. Accessed February 11 2022.https://www.merck.com/news/merck‐announces‐discontinuation‐of‐apecs‐study‐evaluating‐verubecestat‐mk‐8931‐for‐the‐treatment‐of‐people‐with‐prodromal‐alzheimers‐disease/

2. Janssen drops the BACE as Alzheimer's candidate joins fail list;Taylor P;Fierce Biotech,2018

3. Roche.Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) ‐ other company programmes in AD continue 2019. Accessed February 11 2022.https://www.roche.com/media/releases/med‐cor‐2019‐01‐30.htm

4. Biogen.Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer's Disease 2019. Accessed October 7 2021.https://investors.biogen.com/news‐releases/news‐release‐details/biogen‐and‐eisai‐discontinue‐phase‐3‐engage‐and‐emerge‐trials

5. Novartis.Novartis Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention 2019. Accessed February 11 2019.https://www.novartis.com/news/media‐releases/novartis‐amgen‐and‐banner‐alzheimers‐institute‐discontinue‐clinical‐program‐bace‐inhibitor‐cnp520‐alzheimers‐prevention

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease;Annual Review of Medicine;2024-01-29

2. The Lived Experience of Pediatric Gene Therapy: A Scoping Review;Human Gene Therapy;2023-12-01

3. Decision making in clinical trials: Interim analyses, innovative design, and biomarkers;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2023-10

4. Better recognition for research participants: what society should learn from covid-19;BMJ;2023-01-17

5. Supporting participants and study partners when trials end as planned;Alzheimer's & Dementia;2022-11-28